Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
News|Articles|June 2, 2003
- Pharmaceutical Technology-06-02-2003
- Volume 27
- Issue 6
Are you ready for Gen3
Author(s)Hallie Forcinio
The latest generation of packaging equipment boasts technologies surpassing those of its predecessors while offering ease in operation, maintenance, and integration.
Advertisement
Articles in this issue
over 23 years ago
June 2003over 23 years ago
From Genome Exploration to Drug Developmentover 23 years ago
Formulation Development of a Nucleotide Phosphoramidateover 23 years ago
Outsourcing OutlookAdvertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Ask the Expert: Choosing Ingredient Suppliers
5